Join the Anemia - Sickle Cell group to help and get support from people like you.
Anemia - Sickle Cell News
Related terms: Hemoglobin SS disease (Hb SS), Sickle Cell Anemia, Hemoglobin SS disease, Hb SS, SCD
Crude Sickle Cell Birth Prevalence 28.54 per 10,000 in Non-Hispanic Blacks
MONDAY, April 1, 2024 – The crude sickle cell disease (SCD) birth prevalence is 28.54 per 10,000 non-Hispanic Black newborns, according to research published in the March 28 issue of the U.S....
Many Children With Sickle Cell Anemia Do Not Meet Quality Indicators
MONDAY, March 18, 2024 – A number of children with sickle cell anemia (SCA) have low rates of receipt of recommended antibiotic prophylaxis and annual transcranial Doppler (TCD) ultrasound,...
Annual Indirect Economic Burden of Sickle Cell Disease Over $2 Million
WEDNESDAY, March 13, 2024 – Adults with sickle cell disease (SCD) are more likely to report employment loss, and caregivers of children with SCD report more missed days of work, according to a study...
Gene Therapy for Sickle Cell Disease Likely Cost-Effective at
MONDAY, Jan. 22, 2024 – Gene therapy for sickle cell disease (SCD) below $2 million is likely to be cost-effective, according to a study published online Jan. 23 in the Annals of Internal Medicine....
COVID-19 Vaccine Uptake Lagging in Patients With Sickle Cell Disease
FRIDAY, Jan. 19, 2024 – COVID-19 immunization completion is nearly half for people with versus without sickle cell disease (SCD), according to a research letter published online Jan. 8 in JAMA ...
FDA Clears Sickle Cell Drug, Casgevy, to Treat Transfusion-Dependent Beta-Thalassemia
WEDNESDAY, Jan. 17, 2024 – Casgevy, a groundbreaking treatment that was approved to treat sickle cell disease in December, was given the U.S. Food and Drug Administration's blessing on Tuesday to...
COVID Can Threaten Sickle Cell Patients, But Too Few Are Vaccinated
FRIDAY, Jan. 12, 2024 – Sickle cell disease is one of many chronic health conditions that dramatically increases the risk of hospitalization and death in people infected by COVID-19. Unfortunately,...
FDA Approves Lyfgenia (lovotibeglogene autotemcel) for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events
SOMERVILLE, Mass.--(BUSINESS WIRE)--Dec. 8, 2023-- bluebird bio, Inc. (Nasdaq: BLUE) (“bluebird bio” or “bluebird”) today announced the U.S. Food and Drug Administration (FDA) has approved Lyfgenia (p...
FDA Approves Casgevy (exagamglogene autotemcel) CRISPR/Cas9 Genome-Edited Cell Therapy for the Treatment of Sickle Cell Disease
BOSTON & ZUG, Switzerland--(BUSINESS WIRE)--Dec. 8, 2023-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) announced today that the U.S. Food and Drug Admini...
FDA Approves Landmark Sickle Cell Gene Therapies, Casgevy and Lyfgenia
FRIDAY, Dec. 8, 2023 – The U.S. Food and Drug Administration on Friday approved two milestone gene therapies for sickle cell disease, including the first treatment ever approved that uses...
First Gene-Editing Therapies for Sickle Cell Disease, Casgevy and Lyfgenia, Approved by FDA
FRIDAY, Dec. 8, 2023 – Two milestone gene therapies for sickle cell disease have been approved by the U.S. Food and Drug Administration. Casgevy is the first medicine available in the United States...
FDA Approves Landmark Sickle Cell Gene Therapies, Casgevy and Lyfgenia
FRIDAY, Dec. 8, 2023 – The U.S. Food and Drug Administration on Friday approved two milestone gene therapies for sickle cell disease, including the first treatment ever approved that uses...
Disease-Modifying Therapy Use for Sickle Cell Remained Low 2014 to 2021
MONDAY, Nov. 27, 2023 – From 2014 to 2021, uptake of disease-modifying treatments (DMTs) for sickle cell disease (SCD) remained low, according to a study published online Nov. 22 in JAMA Network...
American Academy of Ophthalmology, Nov. 3-5
The annual meeting of the American Academy of Ophthalmology was held from Nov. 3 to 5 in San Francisco and attracted participants from around the world, including ophthalmologists, optometrists,...
AAO: Research Highlights Vision Issues Seen in Pediatric Sickle Cell Disease
THURSDAY, Nov. 9, 2023 – For pediatric patients with sickle cell disease (SCD), ophthalmologic complications include nonproliferative retinopathy (NPR) and proliferative retinopathy (PR), which...
Ask a question
To post your own question to this support group, sign in or create an account.